References
- Schmidt J D, Scott W W, Gibbons R, et al. Chemotherapy programs of the National Prostatic Cancer Project (NPCP). Cancer 1980; 45: 1937–46
- Tannock I F. Is ther evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?. J Clin Oncol 1985; 3: 1013–21
- Byard M A, Smith J J, Drago J R. Chemotesting of prostatic cancer in xenografts. J Surg Oncol 1989; 41: 198–200
- Torti F M, Aston D, Lum B L, et al. Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol 1983; 8: 477–82
- Bastholt L, Dalmark M. Phase II study of Idarubicin given orally in the treatment of anthracycline-naive advanced breast cancer patients. Cancer Treat Rep 1987; 71: 451–4
- Bastholt L, Dalmark M, Jacobsen A, Gadeberg C C, Sandberg E, Mouridsen H T. Weekly oral Idarubicin in postmenopausal women with advanced breast cancer. A phase II study. Acta Oncol 1990; 29: 143–6
- Madsen E L. Painful bone metastasis: Efficacy of radiotherapy assessed by the patients: A randomized trial comparing 4 Gy × 6 versus 10 Gy × 2. Int J Radiat Oncol Biol Phys 1983; 9: 1775–9
- Gibbons R P, Beckley S, Brady M F, et al. The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate. J Surg Oncol 1983; 23: 133–42
- Denis L, Mahler C. Prostatic cancer. An overview. Acta Oncol 1990; 29: 665–77
- Ruff P, Derman D P, Weaving A, Bezwoda W R. Sequential hormone therapy and sequential hormonal and chemotherapy for advanced prostatic cancer. Oncology 1989; 46: 288–92
- Lupera H, Droz J P, Piot G, et al. Phase II trial of combination chemotherapy with fluorouracil (F), doxorubicin (A), and cisplatin (P) (FAP) in hormonally resistant metastatic prostatic adenocarcinoma. Oncology 1989; 46: 372–4